GCG and metabolic disease: The proven health benefits of GLP-1 receptor agonists (GLPRAs), like liraglutide (Saxenda®) and semaglutide (Wegovy®), have transformed the treatment of metabolic disease and its discovery has stimulated development of other GLP-1(7-37)-based therapeutic approaches, including an oral GLPRA, which has shown efficacy (1).